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Abstract
Aims: Elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular disease; however, there is
uncertainty about the role of total triglycerides and the individual triglyceride-containing lipoprotein sub-fractions. We
measured 14 triglyceride-containing lipoprotein sub-fractions using nuclear magnetic resonance and examined associ-
ations with coronary heart disease and stroke.
Methods: Triglyceride-containing sub-fraction measures were available in 11,560 participants from the three UK
cohorts free of coronary heart disease and stroke at baseline. Multivariable logistic regression was used to estimate
the association of each sub-fraction with coronary heart disease and stroke expressed as the odds ratio per standard
deviation increment in the corresponding measure.
Results: The 14 triglyceride-containing sub-fractions were positively correlated with one another and with total trigly-
cerides, and inversely correlated with high-density lipoprotein cholesterol (HDL-C). Thirteen sub-fractions were posi-
tively associated with coronary heart disease (odds ratio in the range 1.12 to 1.22), with the effect estimates for
coronary heart disease being comparable in subgroup analysis of participants with and without type 2 diabetes, and
were attenuated after adjustment for HDL-C and LDL-C. There was no evidence for a clear association of any trigly-
ceride lipoprotein sub-fraction with stroke.
Conclusions: Triglyceride sub-fractions are associated with increased risk of coronary heart disease but not stroke,
with attenuation of effects on adjustment for HDL-C and LDL-C.
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Introduction
Elevated low-density lipoprotein cholesterol (LDL-C)
is thought to play a central role in atherogenesis1 and
is associated with increased risk of coronary heart dis-
ease (CHD) in observational studies, an association
which is robust to adjustment for other risk factors.2
Randomised controlled trials of LDL-C lowering drugs
also now provide compelling evidence of its causal role
in CHD.3 On the other hand, the role of triglycerides in
CHD is less clear. Observational data from a large
meta-analysis of prospective studies also suggest a
higher circulating concentration of triglycerides, and a
lower concentration of high-density lipoprotein choles-
terol (HDL-C) is associated with CHD but the associ-
ation of each is attenuated to the null after adjustment
for the other,2 leading to uncertainty on the nature of
these associations with CHD. However, recently,
Mendelian randomisation studies have suggested a
potential causal association between triglycerides and
CHD,4 which has gained some support following pub-
lication of the findings of the REDUCE-IT trial.5
Total circulating triglyceride concentration is made
up of contributions from a number of different trigly-
ceride-containing lipoprotein sub-fractions which, as
yet, are not routinely measured in clinical practice.
Triglycerides are most abundant in chylomicrons trans-
porting fatty acids from the intestine after a meal, and
very low-density lipoproteins (VLDLs), transporting
triglycerides from the liver.6 In general, the concentra-
tion of triglycerides decreases as the lipid content of
these lipoproteins is hydrolysed and, thus, different
lipoprotein sub-fractions may display different associ-
ations with CHD risk.7
Recently, a high throughput technology was
developed that enables the quantification of triglycer-
ide-containing lipoprotein sub-fractions, among other
lipoprotein subclasses and other metabolites, using
serum nuclear magnetic resonance (NMR).8 A study
based on this platform in a prospective cohort in
China found evidence that the association of triglycer-
ides with CHD may depend on the type of triglyceride-
containing lipoprotein sub-fraction.9 A further study
used the same platform in the Finnish population.10
However, no study to our knowledge has yet
investigated the association of triglyceride-containing
lipoprotein sub-fractions with risk of CHD or stroke
in other populations. The current paper describes an
observational analysis of 14 triglyceride-containing
sub-fraction measurements in 11,560 participants to
investigate potential sub-fraction specific associations
with CHD and stroke in prospective longitudinal
cohort studies from the University College London
(UCL)–Edinburgh–Bristol (UCLEB) Consortium.11
Methods
Study samples
The design and data collection for the UCLEB
Consortium of longitudinal population studies has
been described previously.11 NMR metabolite measure-
ments for the current analysis were available in 11,560
participants enrolled in the British Regional Heart
Study,12 including men aged 60–79 years at metabolite
assessment in 1998–2000 and seven years of follow-up;
the Whitehall II study,11 including UK government
workers aged 45 to 69 years at metabolite assessment
in 1997–1999 and seven years of follow-up; and The
Southall And Brent REvisited Study13 (SABRE), a
tri-ethnic study including British men and women of
European (SABRE1), South Asian (SABRE2) and
African-Caribbean descent (SABRE3), with 20 years
of follow-up.
Metabolite quantification
The Nightingale high-throughput NMR metabolomics
platform was used to quantify concentrations of total
and 14 triglyceride-containing lipoprotein sub-fraction
metabolomics measures (referred to as triglyceride sub-
fractions from here onwards) from serum samples in
either fasting or non-fasting states in all contributing
studies. Apolipoprotein A1 (apoA1) and B (apoB) were
measured using the same platform. Detailed experimen-
tal protocols and application of the metabolomics plat-
form method have been described and reviewed
elsewhere.8,14,15
Participant characteristics
The following participant information was recorded at
time of metabolite measurement: age (years), sex, life-
style factors; smoking (categorised here as ever/never)
and alcohol (ever/never); body mass index (BMI;
kg/m2); and systolic and diastolic blood pressure
(mmHg) and type 2 diabetes mellitus (yes/no).
Standard clinical chemistry was used to measure
LDL-C and HDL-C (mmol/L) and serum triglycerides
(mmol/L). This included, in all three studies,
LDL-C levels being estimated using Friedwald’s
equation from total cholesterol and triglycerides
(LDL-C¼ total cholesterol – (triglyceride/5) – HDL).16
Outcomes
Incident CHD was defined as the first occurrence of
fatal or non-fatal myocardial infarction (MI), or cor-
onary revascularisation. Incident stroke was defined as
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the first occurrence of fatal or non-fatal ischaemic or
haemorrhagic stroke. Methods of disease ascertainment
for contributing UCLEB cohorts are described in detail
elsewhere.11
Statistical analysis
We first assessed the study-specific distribution of each
triglyceride sub-fraction (Figure 1). On finding agree-
ment across studies, sub-fraction measurements were
mean centred and standardised to an SD of 1.
Spearman’s correlation coefficient (rs) was used to
explore associations between the 14 triglyceride sub-
fractions, NMR-measured total serum triglyceride,
and various participant characteristics. Study-specific
logistic regression was used to estimate the odds ratio
(OR) and 95% confidence interval (CI) with CHD and
stroke. Estimates were synthesised across cohorts, using
the fixed-effect inverse variance weighted estimator. We
evaluated different multivariable logistic regression
BRHS
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Figure 1. Distributions of 14 triglyceride sub-fractions.
Histograms show study specific distribution (mmol/L) of each nuclear magnetic resonance triglyceride sub-fraction.
BRHS: British Regional Heart Study; WHII: Whitehall II study; SABRE: The Southall And Brent REvisited Study; VLDL: very low-density
lipoprotein; IDL: intermediate-density lipoprotein; HDL: high-density lipoprotein.
Joshi et al. 3
models to assess how much of the association with
CHD and stroke remained after accounting for
known CVD risk factors, specifically; age and sex
(model 1), model 1 with additional correction for
BMI, smoking, systolic blood pressure (SBP) and type
2 diabetes (model 2). For comparisons with previous
meta-analysis2 and to assess independent association
of the 14 sub-fraction associations with CHD, we sub-
sequently conditioned on LDL-C and HDL-C meas-
urements (model 3) or apoA1 and apoB (model 4).
Given the potential influence of food intake on the con-
centration of circulating triglyceride sub-fractions, we
compared the association of fasted and non-fasted tri-
glyceride sub-fractions with CHD and stroke using
data from the SABRE study. There is a reported inter-
action of diabetes and triglycerides;17 we performed a
type 2 diabetes stratified analysis to determine whether
such an interaction was present for the 14 triglyceride
sub-fractions and CHD.
Analysis was conducted using R studio version
1.1.4231,8 using the following packages: visualise the
correlation matrix (Corrplot),19 conduct meta-analyses
(Metafor).20
Results
The association of the 14 triglyceride sub-fractions and
total NMR-measured triglycerides with CHD and
stroke was assessed in a sample of 11,560 participants,
of which 1031 experienced CHD and 582 stroke. The
mean age was 58 (SD: 9.2) years, 7634 (66%) were men,
mean BMI was 26.4 (SD: 3.8), and average SBP was
131 (SD: 22.7) mmHg; see Table 1.
The triglyceride sub-fractions showed positive cor-
relations with one another (Figure 2), and clinical
chemistry-measured lipid measurements. For example,
triglycerides in extremely large VLDL was positively
correlated with 12 sub-fractions with rs in the range
of 0.33 to 0.91. Various participant characteristics
were correlated with triglyceride sub-fractions
(rs range 0.01 to 0.32), specifically BMI was positively
correlated 14 triglyceride sub-fractions (rs in the range
0.10 to 0.32). With the exception of triglycerides in
large HDL, the remaining triglyceride sub-fractions
(mainly in the VLDL subclass) exhibited a negative
correlation with HDL-C (rs range 0.42 to 0.33).
Associations of triglyceride sub-fractions with CHD
and stroke
In age and sex adjusted analysis total triglycerides and
all triglyceride sub-fractions, with the exception of tri-
glycerides in large HDL, were associated with an
increased risk of CHD (Figure 3). There was low to
moderate (I2< 50%) heterogeneity for 13 sub-fraction
estimates with CHD and stroke (Supplementary
Material Table 1 online) and high heterogeneity
(I2> 70%) in estimates for the large HDL sub-fraction.
After additional adjustments for BMI, SBP, smoking
and type 2 diabetes (model 2), effect estimates attenu-
ated towards the null, with ORs in the range of 0.98 to
1.22. Triglycerides in the small and medium HDL sub-
class were associated with an increased risk of CHD,
whereas triglycerides in large HDL were inversely asso-
ciated. Medium and large HDL sub-fractions did not
exclude a neutral-effect. We determined to what extent
LDL-C and HDL-C explained the independent associ-
ation of triglyceride sub-fraction with CHD. Compared
with model 2, additionally conditioning on LDL-C and
HDL-C attenuated CHD ORs, with none of the 14
estimates showing convincing evidence of an independ-
ent effect (Supplementary Figure 1). We further
explored the influence of replacing LDL-C and HDL-
C with apoB and apoA1, which are considered more
precise measurements. However, adjustment for apoA1
and apoB, rather than for HDL-C and LDL-C respect-
ively, did not meaningfully change the results
(Supplementary Figure 2), with one possible exception
of triglycerides in the VLDL subclass for which the
direction of associations changed. For example,
accounting for LDL-C and HDL-C, ORs were in the
range of 1.01 to 1.04, whereas adjustment of apoA1 and
apoB yielded negative associations in the range of 0.96
to 0.99.
Associations of total and 14 triglyceride sub-
fractions with stroke were smaller than those observed
for CHD (Figure 3), with considerable attenuation in
both direction and magnitude, after adjustments for
SBP, BMI, smoking and type 2 diabetes (model 2)
none were statistically significant.
Effect estimates of 14 triglyceride sub-fractions with
CHD were comparable in direction and pattern of asso-
ciation using triglyceride measures quantified in the
fasting and non-fasting state (Supplementary Figure 3).
The effect estimates of total serum triglycerides with
CHD measured using NMR methods versus clinical
chemistry methods were comparable in direction and
magnitude of effect (NMR measured total triglyceride:
OR 1.19, 95% CI 1.10 to 1.28, versus clinical chemistry
measured total triglyceride: OR 1.11, 95% CI 1.07 to
1.21 (Supplementary Table 2).
CHD associations in participants with and without
type 2 diabetes
Given associations of triglyceride sub-fractions with
CHD, we explored evidence of differences in effect in
a type 2 diabetes (T2DM) stratified analysis (1071
T2DM participants vs. 10,347 non-T2DM partici-
pants). We did not find evidence of an interaction
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between triglyceride sub-fractions and diabetes with
CHD risk (Table 2). Triglyceride concentration in 13
sub-fractions was positively associated with CHD in
participants with and without T2DM, although effect
estimates for the non-T2DM subgroup had wide 95%
CIs that frequently included unity due to the compara-
tively small sample size.
Discussion
We found that total triglyceride and most triglyceride
sub-fractions (with the exception of triglyceride in the
HDL subclass) were associated with an increased risk
of CHD. These associations persisted after accounting
for differences in age, sex, SBP, BMI, smoking and
T2DM, ranging from a CHD OR of 1.12 to 1.22.
Importantly, triglyceride within the VLDL subclass
had the strongest association with CHD (OR in the
range of 1.12 to 1.22), which is consistent with the
view that VLDL particles are particularly athero-
genic.21,22 Accounting for HDL-C and LDL-C attenu-
ated the CHD associations towards the null, suggesting
that triglyceride associations are not independent of
LDL-C and HDL-C. While such analyses may suggest
an absence of a direct pathway, that is, independent of
LDL-C and HDL-C, an alternative explanation for this
attenuation may be found in the different variability of
triglyceride measurements compared with HDL-C.23
Biological variability in triglyceride measurements, the
extent of which we were not able to assess here, has
previously been reported with a median variation of
23.5% and is a consideration when evaluating the
role of triglycerides in CVD risk.22 We did not
observe any interaction between T2DM status and
the sub-fraction associations with CHD.
Consistent with a previous study,9 concentrations of
triglycerides within large and medium HDL particles
did not show an association with risk of CHD.
Table 1. Description of study populations.
SABRE2
N¼ 1526
SABRE1
N¼ 1561
SABRE3
N¼ 192
WHII
N¼ 4728
BRHS
N¼ 3553
Total participant
sample
N¼ 11,560
Missing
%
Age, years 51.1 (7.0) 53.2 (7.3) 53.3 (5.7) 55.5 (6.0) 68.7 (5.5) 58.6 (9.2) 0.00
Sex, male (%) 1278 (83.8) 1356 (86.9) 180 (93.8) 1267 (26.8) 3553 (100) 7634 (66.0) 0.00
BMI, kg/m2 26.1 (3.6) 26.1 (3.9) 26.8 (3.7) 26.1 (3.9) 26.9 (3.6) 26.4 (3.8) 0.06
Smoking, ever 349 (22.9) 1097 (70.3) 79 (41.4) 617 (14.6) 2521 (71.1) 4663 (42.2) 0.04
Alcohol, ever 899 (59.3) 1467 (94.0) 176 (92.2) 4244 (91) 3145 (90.4) 9931 (87.0) 0.01
Type 2 diabetes, (%) 318 (20.1) 86 (5.5) 37 (19.3) 251 (5.3) 379 (11.1) 1071 (9.4) 0.01
SBP, mmHg 125.2 (18.2) 123.0 (17.1) 128.4 (18.7) 122.9 (16.1) 149.2 (24.2) 131.3 (22.7) 0.00
DBP, mmHg 80.1 (10.6) 76.8 (10.6) 81.5 (12.4) 77.4 (10.3) 85.3 (11.2) 80.2 (11.3) 0.00
HbA1c, mmol/L 6.2 (1.3) 5.6 (0.6) 6.0 (0.8) – 5.0 (0.9) 5.4 (1.0) 0.46
CRP, mg/L 2.0 (3.7) 3.4 (6.5) 2.6 (5.2) 0.29
IL-6, pg/mL 1.8 (1.5) 3.2 (3.0) 2.4 (2.4) 0.29
Clinical chemistry measured lipids
Total cholesterol, mmol/La 5.9 (5.2, 6.6) 6.1 (5.4, 6.8) 5.8 (5.1, 6.6) 5.8 (5.2, 6.6) 6.0 (5.4, 6.7) 5.9 (5.3, 6.6) 0.00
LDL-C, mmol/La 3.8 (3.2, 4.4) 4.0 (3.4, 4.7 3.8 (3.2, 4.5) 3.8 (3.2, 4.4) 3.9 (3.3, 4.5) 3.8 (3.3, 4.5) 0.00
HDL-C, mmol/La 1.2 (1.0, 1.4) 1.3 (1.1, 1.5) 1.4 (1.1, 1.6) 1.4 (1.2, 1.7) 1.3 (1.1, 1.5) 1.3 (1.1, 1.6) 0.06
TG, mmol/La 1.7 (1.2, 2.5) 1.4 (1.0, 2.1) 1.1 (0.8, 1.5) 1.1 (0.8, 1.6) 1.6 (1.2, 2.2) 1.4 (1.0, 2.0) 0.05
NMR-measured lipids
Total cholesterol, mmol/La 3.8 (3.3, 4.4) 4.1 (3.5, 4.6) 3.8 (3.2, 4.4) 5.1 (4.5, 5.6) 4.6 (4.0, 5.2) 4.6 (3.9, 5.3 0.00
TG, mmol/La 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 0.8 (0.6, 0.9) 1.2 (0.9, 1.5) 1.4 (1.1, 1.9) 1.2 (0.9, 1.5) 0.00
Apolipoprotein A1, mmol/La 1.2 (1.1, 1.3) 1.2 (1.1, 1.3) 1.2 (1.1, 1.3) 1.6 (1.5, 1.7) 1.4 (1.3, 1.5) 1.4 (1.3, 1.6) 0.00
Apolipoprotein B, mmol/La 0.8 (0.7, 0.9) 0.8 (0.7, 1.0) 0.8 (0.7, 0.9) 1.0 (0.9, 1.1) 1.0 (0.8, 1.1) 0.9 (0.8, 1.1) 0.00
CHD, events/n 317/919
(17.4)
189/1035
(15.4)
23/109
(17.4)
122/4200
(2.8)
380/3173
(10.7)
1031/10,467
(9.9)
0.09
Stroke, events/n 136/1191
(10.2)
119/1212
(8.9)
10/118
(13.2)
68/4646
(1.4)
241/3312
(6.8)
582/10,479
(5.3)
0.04
Values are mean SD, or %.
aMedian (interquartile range).
SABRE: The Southall And Brent REvisited Study; WHII: the Whitehall II study; BRHS: British Regional Heart Study; BMI: body mass index; SBP: systolic
blood pressure; DBP: diastolic blood pressure; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: trigly-
cerides; CRP: C-reactive protein; IL-6: interleukin-6; CHD: coronary heart disease.
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Measures in the HDL sub-fraction likely represents the
role of HDL particles that mediates reverse cholesterol
transport, a different process from that indexed by the
other sub-fractions. In relation to reverse cholesterol
transport, variants in the cholesteryl ester transfer pro-
tein (CETP) gene and treatment with a potent, target-
specific CETP inhibitor for a sufficient duration, both
result in reduced triglycerides, LDL-C and apoB, ele-
vated HDL-C and apoA1 and reduced CHD risk.24
The apparent inconsistency of associations of total
triglycerides and CHD2 and uncertainty about causal
relationships may be due in part to the complexity of
triglyceride absorption and metabolism, and a poten-
tially heterogeneous role of different triglyceride-con-
taining lipoproteins in atherogenesis. Conventional
measures of total serum triglyceride levels do not take
into account the differing lipoprotein compositions
with the same detailed precision as NMR technology
and, thus, standard clinical chemistry measurement
processes may not sufficiently delineate the relationship
of individual lipoproteins with CHD. To evaluate this,
we assessed the association of total serum triglycerides
measured using clinical chemistry methods and NMR
methods and report comparable effects despite the
absolute difference in total serum triglyceride concen-
tration between the two methods.
Triglycerides are most abundant in chylomicrons
transporting fatty acids from the intestine, and
VLDLs, transporting triglycerides from the liver.6 In
general, the triglyceride content of lipoprotein
sub-fractions decreases as the lipid pools of these lipo-
proteins are hydrolysed and, thus, different lipoproteins
may be associated with differential CHD risk.7
Increases in total triglycerides may reflect an increase
in the triglyceride content of lipoproteins, or an
increase in the total number of triglyceride-rich (pre-
dominantly VLDL) particles. In addition, an emerging
view is that the remnant cholesterol content (that can
be proxied by total cholesterol – HDL-C – LDL-C) in
triglyceride-rich lipoprotein in addition to triglycerides,
has pro-atherogenic actions.6,25,26 A suggested mechan-
ism is that triglycerides can penetrate the arterial intima
and trigger inflammation, but are then metabolised,
whereas the cholesterol remnants are not, promoting
foam cell formation, atherosclerotic plaques and ultim-
ately CHD.27
It has been suggested that apoB (which increases the
total number of atherogenic particles) is more robustly
associated with CHD than other measures.28 However,
we observed associations that were comparable in dir-
ection and magnitude for CHD, regardless of whether
adjustments were for LDL-C and HDL-C or apoA1 or
apoB, with the possible exception of triglyceride in the
VLDL subclass.
In contrast to associations with CHD, we found no
convincing evidence of an association between trigly-
ceride sub-fractions and risk of stroke. The magnitude
of unadjusted and adjusted associations for stroke were
all weaker than for CHD and also showed greater
variation in direction between the triglyceride
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Figure 2. Correlation matrix heat map of 14 triglyceride sub-fractions and study variables.
Heat map matrix represents Spearman’s correlations.
VLDL: very low-density lipoprotein; IDL: intermediate-density lipoprotein; LDL: low-density lipoprotein; HDL: high-density
lipoprotein; LDL-C: LDL cholesterol; HDL-C: HDL cholesterol; BMI: body mass index.
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sub-fractions. However, it is possible that large studies
with more stroke events might find evidence of a
modest association of certain sub-fractions with
stroke risk.
We compare the results presented here to existing
knowledge in this area. A study using Finnish partici-
pant data to examine the association of circulating
metabolites and cardiovascular disease (CVD) reported
CHD Stroke
Trigylceride sub-fraction
Extremely large VLDL
Very large VLDL
Large VLDL
Medium VLDL
Small VLDL
Very small VLDL
IDL
Large LDL
Medium LDL
Small LDL
Very large HDL
Large HDL
Medium HDL
Small HDL
Total serum TG
0.8 1 1.2 1.4 0.8 1 1.2 1.4
OR (95% CI) OR (95% CI)
1.15 (1.08, 1.22)
1.12 (1.05, 1.19)
1.15 (1.08, 1.23)
1.12 (1.04, 1.20)
1.15 (1.07, 1.24)
1.12 (1.03, 1.21)
1.18 (1.10, 1.27)
1.16 (1.07, 1.25)
1.23 (1.14, 1.32)
1.20 (1.11, 1.30)
1.26 (1.17, 1.36)
1.22 (1.13, 1.32)
1.26 (1.17, 1.34)
1.21 (1.12, 1.30)
1.20 (1.12, 1.28)
1.15 (1.08, 1.24)
1.17 (1.10, 1.25)
1.13 (1.05, 1.21)
1.22 (1.14, 1.30)
1.17 (1.09, 1.25)
1.15 (1.07, 1.23)
1.12 (1.05, 1.21)
0.98 (0.89, 1.07)
0.98 (0.88, 1.08)
1.11 (1.03, 1.19)
1.05 (0.96, 1.13)
1.03 (0.95, 1.11)
0.97 (0.89, 1.06)
1.02 (0.93, 1.11)
0.95 (0.87, 1.05)
1.00 (0.91, 1.10)
0.92 (0.83, 1.02)
0.97 (0.88, 1.07)
0.90 (0.81, 1.00)
0.97 (0.88, 1.07)
0.90 (0.81, 1.00)
1.02 (0.93, 1.13)
0.95 (0.85, 1.05)
1.07 (0.97, 1.17)
0.99 (0.90, 1.09)
1.10 (1.01, 1.20)
1.03 (0.94, 1.13)
1.09 (1.00, 1.18)
1.02 (0.93, 1.12)
1.07 (0.98, 1.17)
1.00 (0.91, 1.09)
1.02 (0.93, 1.12)
0.96 (0.88, 1.06)
1.05 (0.93, 1.18)
1.02 (0.90, 1.16)
1.00 (0.91, 1.11)
0.92 (0.83, 1.03)
1.13 (1.02, 1.25)
1.01 (0.90, 1.13)
1.01 (0.92, 1.11)
0.93 (0.83, 1.03)
1.26 (1.17, 1.36)
1.19 (1.09, 1.29)
1.23 (1.14, 1.32)
1.19 (1.10, 1.28)
(a) (b)
Figure 3. Nuclear magnetic resonance-measured total and 14 triglyceride sub-fraction associations with coronary heart disease and
stroke.
Effect estimates are presented as odds ratios with 95% confidence intervals per one standard deviation increase in the analyte for
coronary heart disease (a) and stroke (b). Models are adjusted for: age and sex (model 1, denoted by blue bar), model 1 with additional
correction for smoking status, body mass index, systolic blood pressure and type 2 diabetes (model 2, denoted by orange bar).
CHD: coronary heart disease; OR: odds ratio; CI: confidence interval; VLDL: very low-density lipoprotein; IDL: intermediate-density
lipoprotein; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG: triglyceride.
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age and sex adjusted associations of triglycerides and
incident CVD10 (800 cases/7,256 participants; hazard
ratio: 1.25, 95% CI: 1.13 to 1.35). Similar to the find-
ings presented here, Wurtz et al. report that triglyceride
associations with CHD attenuate towards the null
when performing additional adjustment for HDL-C.
A recent study in participants from a Chinese cohort
(912 cases/4662 participants) demonstrated consistent
associations of triglyceride sub-fractions and incident
MI after controlling for age, sex, fasting hours,
region, smoking status and educational attainment
(OR per 1 SD increase in the metabolite in the range
1.03–1.31);9 however, effect estimates attenuated
towards the null with additional adjustment for SBP
and BMI. The present study, although not controlling
for fasting hours or educational attainment, identified
comparable effect estimates which remained robust to
adjustments for SBP and BMI.
This study has several strengths. We observed no
large variation in the distribution of the 14 triglyceride
sub-fractions when combining study specific distribu-
tions, indicating homogeneity in the spread of the 14
triglyceride sub-fractions and no discernible differences
in the contributing populations from which the samples
were derived. We include a tri-ethnic cohort and report
a similar distribution of each analyte irrespective of
ethnic group. Our findings were consistent with those
reported by Holmes et al.9 and Wurtz et al.10 but
included a larger sample size for CHD (CHD 1031
cases/10,467 controls, stroke 582 cases/10,479 controls)
compared with Holmes et al. (MI 912 cases/1466
controls and ischaemic stroke 1146 cases/1466 controls)
and Wurtz et al. (CVD 800 cases/7256 controls),
thereby increasing precision in the effect estimates we
present here. We also extend the investigation of the
relationship between triglyceride-containing lipoprotein
sub-fractions beyond ethnically distinct Finnish and
Chinese populations. Here we demonstrate consistent
findings using data from multiple cohorts across
multiple ethnicities consisting of European, South-
Asian and African-Caribbean descent, and across
differing age groups.
Study limitations
Some limitations deserve consideration. Total triglycer-
ides and triglyceride-containing lipoprotein sub-fraction
concentration in plasma samples are affected by food
intake.6 Despite this, in a stratified analysis, we deter-
mined similar associations of triglyceride-containing
lipoprotein subfractions with CHD and stroke among
fasted and non-fasted subjects from the SABRE study.
In this study stroke was defined as a composite of
ischaemic and haemorrhagic stroke. Lower triglyceride
concentrations have been shown to be associated with
decreased risk of haemorrhagic stroke, whereas higher
triglyceride associated with increased risk of ischaemic
Table 2. Effect estimates and upper and lower 95% confidence interval in subgroup participant population of type 2
diabetes and risk of coronary heart disease.
Type 2 diabetes
N¼ 1071
No type 2 diabetes
N¼ 10,347 p value for
interactionCHD OR (95% CI) CHD OR (95% CI)
Extremely large VLDL 1.05 (0.92, 1.20) 1.14 (1.06, 1.22) 0.286
Very large VLDL 1.04 (0.91, 1.18) 1.13 (1.04, 1.22) 0.262
Large VLDL 1.02 (0.88, 1.18) 1.13 (1.04, 1.23) 0.201
Medium VLDL 1.05 (0.91, 1.22) 1.17 (1.08, 1.28) 0.168
Small VLDL 1.11 (0.94, 1.30) 1.22 (1.13, 1.33) 0.261
Very small VLDL 1.15 (0.96, 1.36) 1.25 (1.15, 1.36) 0.364
IDL 1.22 (1.04, 1.43) 1.21 (1.12, 1.31) 0.903
Large LDL 1.19 (1.02, 1.39) 1.15 (1.06, 1.24) 0.667
Medium LDL 1.11 (0.95, 1.29) 1.13 (1.05, 1.22) 0.812
Small LDL 1.16 (1.00, 1.36) 1.17 (1.08, 1.26) 0.954
Very large HDL 1.08 (0.92, 1.25) 1.11 (1.03, 1.20) 0.685
Large HDL 0.91 (0.73, 1.14) 0.94 (0.85, 1.04) 0.814
Medium HDL 0.94 (0.78, 1.13) 1.05 (0.96, 1.14) 0.264
Small HDL 1.12 (0.94, 1.33) 1.21 (1.11, 1.33) 0.380
Estimates are odds ratios and (upper and lower bands). Odds ratios are adjusted for: age, sex, body mass index, smoking status, alcohol,
systolic blood pressure.
CHD: coronary heart disease; OR: odds ratio; CI: confidence interval; VLDL: very-low-density lipoprotein; IDL: intermediate-density
lipoprotein; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
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stroke.29 We were unable to differentiate types of stroke
in this study (in which typically there is a 4:1 ratio of
ischaemic to haemorrhagic stroke events); as such the
null effect estimates presented here may not reflect the
true association of triglycerides and ischaemic stroke.
In addition, we were unable to account for lipid low-
ering medication or socio-economic position as has
been conducted in previous work10 and may modify
the effect of triglyceride sub-fraction associations with
CHD, therefore it is possible that observed associations
may be explained by residual confounding due to fac-
tors not included in this study.
Conclusions
In conclusion, we demonstrate risk-increasing associ-
ations of 13 triglyceride sub-fractions with CHD, with
varying effect estimates between sub-fractions, the
strongest being for the triglycerides in the VLDL sub-
fraction. By contrast, we did not observe similar asso-
ciations for stroke. Further studies, for example using
Mendelian randomisation, could assess which (if any)
of the associations is causal, and if any causal associ-
ations might be modifiable by new or existing drugs.
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